Search Results - "Sivolapenko, Gregory B."
-
1
VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
Published in International journal of molecular sciences (18-11-2019)“…Bevacizumab is used to treat metastatic colorectal cancer (mCRC). However, there are still no available predictors of clinical outcomes. We investigated…”
Get full text
Journal Article -
2
Machine learning‐guided covariate selection for time‐to‐event models developed from a small sample of real‐world patients receiving bevacizumab treatment
Published in CPT: pharmacometrics and systems pharmacology (01-10-2022)“…Therapeutic outcomes in patients with metastatic colorectal cancer (mCRC) receiving bevacizumab treatment are highly variable, and a reliable predictive factor…”
Get full text
Journal Article -
3
Aqueous Humour Ofloxacin Concentration after Topical Instillation in Patients with Dry Eye Disease
Published in Medicina (Kaunas, Lithuania) (01-08-2022)“…Background and Objectives: A prospective, randomized clinical trial was conducted to evaluate the concentration of ofloxacin in the aqueous humour (AqH) of…”
Get full text
Journal Article -
4
Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review
Published in Journal of personalized medicine (01-09-2020)“…Bevacizumab is a monoclonal antibody that targets VEGF-A and inhibits tumor angiogenesis. Bevacizumab is approved for the treatment of various cancer,…”
Get full text
Journal Article -
5
Development and validation of analytical methodologies for the quantification of PCK3145 and PEG-PCK3145 in mice
Published in Analytical biochemistry (01-01-2019)“…PCK3145 is an anti-metastatic synthetic peptide against prostate cancer. The objective of the study is to develop and validate novel and sensitive methods for…”
Get full text
Journal Article -
6
Inhibition of the angiotensin II type 2 receptor AT2R is a novel therapeutic strategy for glioblastoma
Published in Proceedings of the National Academy of Sciences - PNAS (09-08-2022)“…Glioblastoma (GBM) is an aggressive malignant primary brain tumor with limited therapeutic options. We show that the angiotensin II (AngII) type 2 receptor…”
Get full text
Journal Article -
7
Inhibition of the angiotensin II type 2 receptor AT 2 R is a novel therapeutic strategy for glioblastoma
Published in Proceedings of the National Academy of Sciences - PNAS (09-08-2022)“…Glioblastoma (GBM) is an aggressive malignant primary brain tumor with limited therapeutic options. We show that the angiotensin II (AngII) type 2 receptor (AT…”
Get full text
Journal Article -
8
In vivo quantification and pharmacokinetic studies of cotinine in mice after smoke exposure by LC–MS/MS
Published in Biomedical chromatography (01-02-2020)“…A sensitive analytical method was developed and validated for the quantification of cotinine in mouse plasma after exposure to smoke of 0.5, 1.0, and 1.5…”
Get full text
Journal Article -
9
Development and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient plasma samples
Published in Journal of pharmaceutical and biomedical analysis (05-01-2019)“…•Development of two cost-effective methods for quantitation of TMZ in human plasma.•A simple protein precipitation step is used in the sample preparation.•The…”
Get full text
Journal Article -
10
Development of a validated LC-MS/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients
Published in Journal of pharmaceutical and biomedical analysis (05-02-2019)“…•A cost-effective and rapid bioanalytical method for quantitation of sunitinib.•A simple protein precipitation step is used in the sample preparation.•The…”
Get full text
Journal Article -
11
Development of a novel conjugatable sunitinib analogue validated through in vitro and in vivo preclinical settings
Published in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (15-08-2018)“…Sunitinib is an oral FDA/EMEA approved multi-targeted tyrosine kinase inhibitor. It possesses anti-angiogenic and antitumor activity against a variety of…”
Get full text
Journal Article -
12
Co-administration of succinylated gelatine with a (99m)Tc-bombesin analogue, effects on pharmacokinetics and tumor uptake
Published in Nuclear medicine and biology (01-10-2016)“…The bombesin analogue, [(99m)Tc-GGC]-(Ornithine)3-BN(2-14), (99m)Tc-BN-O, targeting gastrin releasing peptide receptors (GRPrs) on the surface of tumors, was…”
Get full text
Journal Article -
13
Structural modifications of 99mTc-labelled bombesin-like peptides for optimizing pharmacokinetics in prostate tumor targeting
Published in International journal of pharmaceutics (01-07-2012)“…The main goal of the present study was to investigate the importance of the addition of a positively charged aa in the naturally occurring Bombesin (BN)…”
Get full text
Journal Article -
14
Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response
Published in Breast (Edinburgh) (01-06-2007)“…Summary Mammoscintigraphy (MMS) has been indicated as a useful tool in predicting response to therapy in cancer. However, contrasting results have been…”
Get full text
Journal Article -
15
Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide
Published in European journal of nuclear medicine (01-10-1998)“…Integrins are cell-surface glycoproteins found in different forms on all cells except erythrocytes. Integrins bind to cell adhesion molecules and to proteins…”
Get full text
Journal Article -
16
Co-administration of succinylated gelatine with a 99mTc-bombesin analogue, effects on pharmacokinetics and tumor uptake
Published in Nuclear medicine and biology (01-10-2016)“…The bombesin analogue, [99mTc-GGC]-(Ornithine)3-BN(2-14), 99mTc-BN-O, targeting gastrin releasing peptide receptors (GRPrs) on the surface of tumors, was…”
Get full text
Journal Article -
17
Co-administration of succinylated gelatine with a 99m Tc-bombesin analogue, effects on pharmacokinetics and tumor uptake
Published in Nuclear medicine and biology (01-10-2016)Get full text
Journal Article -
18
Co-administration of succinylated gelatine with a99m Tc-bombesin analogue, effects on pharmacokinetics and tumor uptake
Published in Nuclear medicine and biology (2016)“…Abstract The bombesin analogue, [99m Tc-GGC]-(Ornithine)3 -BN(2-14), 99m Tc-BN-O , targeting gastrin releasing peptide receptors (GRPrs) on the surface of…”
Get full text
Journal Article -
19
Clearance of 131I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody
Published in Cancer research (Chicago, Ill.) (01-02-1990)“…Five patients treated with intraperitoneal 131I-labeled mouse monoclonal antibody for ovarian cancer also received i.v. exogenous polyclonal human anti-murine…”
Get full text
Journal Article -
20
A study of in vivo immune complex formation and clearance in man
Published in The Journal of immunology (1950) (15-06-1990)“…C and CR1 have been shown to participate in the clearance of injected, preformed, immune complexes in humans and in non-human primates. Their role in the…”
Get full text
Journal Article